MDT

101.61

+1.73%↑

139.25

+1.19%↑

VEEV

224.03

+2.75%↑

HQY

86.42

+1.84%↑

NEOG

9.98

+3.21%↑

MDT

101.61

+1.73%↑

139.25

+1.19%↑

VEEV

224.03

+2.75%↑

HQY

86.42

+1.84%↑

NEOG

9.98

+3.21%↑

MDT

101.61

+1.73%↑

139.25

+1.19%↑

VEEV

224.03

+2.75%↑

HQY

86.42

+1.84%↑

NEOG

9.98

+3.21%↑

MDT

101.61

+1.73%↑

139.25

+1.19%↑

VEEV

224.03

+2.75%↑

HQY

86.42

+1.84%↑

NEOG

9.98

+3.21%↑

MDT

101.61

+1.73%↑

139.25

+1.19%↑

VEEV

224.03

+2.75%↑

HQY

86.42

+1.84%↑

NEOG

9.98

+3.21%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.31 3.97

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.24

Max

1.33

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+134.38% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-23M 79M
Vorheriger Eröffnungskurs	-2.66
Vorheriger Schlusskurs	1.31

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Jan. 2026, 23:49 UTC

Wichtige Markttreiber

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. Jan. 2026, 21:12 UTC

Wichtige Markttreiber

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. Jan. 2026, 20:29 UTC

Wichtige Markttreiber

Chip Makers Gain After Trump Calls Off European Tariffs

21. Jan. 2026, 20:04 UTC

Wichtige Markttreiber

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. Jan. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. Jan. 2026, 22:39 UTC

Ergebnisse

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Jan. 2026, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. Jan. 2026, 21:19 UTC

Ergebnisse

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. Jan. 2026, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. Jan. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. Jan. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. Jan. 2026, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. Jan. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Jan. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. Jan. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. Jan. 2026, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. Jan. 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. Jan. 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Group Agrees to Buy Allfunds

21. Jan. 2026, 20:08 UTC

Ergebnisse

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. Jan. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. Jan. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. Jan. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. Jan. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. Jan. 2026, 19:24 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. Jan. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. Jan. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

134.38% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 134.38%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.